• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
LXRX

LXRX

Lexicon Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.85

-0.04 (-2.12%)

Rating:C-

Company Profile

CEO

Michael S. Exton

IPO Date

2000-04-07

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.89

Prev. Close

$1.89

Day Low

$1.81

Day High

$1.93

52W Low

$0.64

52W High

$2.53

Market Cap

$0.82B

Volume

2.65M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

28.7%

Avg Negative

3.8%

Avg Neutral

67.5%

News Feed

Lexicon Pharmaceuticals: Q2 Earnings Insights

Benzinga·7/30/2021·↑ positive

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer

GlobeNewsWire·7/30/2021·↑ positive

Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update

GlobeNewsWire·7/30/2021
·↓ negative

Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021

GlobeNewsWire·7/28/2021·↓ negative

LXRX Stock Price Increased 18.67%: Why It Happened

Pulse2·6/26/2021·↑ positive

Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions

GlobeNewsWire·6/25/2021·↑ positive

Lexicon Pharmaceuticals Still A Very High-Risk/High-Reward Biopharma Name

Seeking Alpha·5/27/2021·↑ positive

Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology's 70th Annual Scientific Session

GlobeNewsWire·5/13/2021·↑ positive

Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/7/2021·↓ negative

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive